Ruanxin Biotechnology
Hyaluronic acid and chondroitin sulfate production supplier.
About Ruanxin Biotechnology
Shandong Ruanxin (Runxin) Biotechnology Co., Ltd. is a global supplier and manufacturer specializing in the production and research of sodium hyaluronate and chondroitin sulfate. The company was established in 1998 and is located in Qufu City, Shandong Province, China. Its predecessor was a casing plant in the 1950s that exported products to Western countries. The company began producing chondroitin sulfate and heparin sodium in 1998, started its own hyaluronic acid (HA) production in 2006, and in 2012, it began offering OEM processing and export services after constructing a D-level (100,000 level) GMP workshop.
Ruanxin Biotechnology's business model encompasses the research and development, production, and sales of its core products. The company serves a global market, providing raw materials and finished products to various industries. Its offerings include different grades of sodium hyaluronate powder (pharmaceutical, injection, eye drop, cosmetic, and food grade) and chondroitin sulfate. The company's products are used in medical cosmetology for skin filling and facial atrophy improvement, as well as in orthopedics for treating joint injuries and early osteoarthritis. They also manufacture products for veterinary applications, including for horses and other pets. Additionally, their materials are used in ophthalmic surgery and as anti-adhesion gels.
A significant part of Ruanxin's business is its comprehensive OEM and ODM (private label) services. This includes customized formulation development, packaging design, and quality control to meet specific client requirements for products like sodium hyaluronate injectable gels. The company provides extensive after-sales support, including detailed product instructions, technical support, and management of quality issues. Buttressed by a highly productive R&D team and a fully equipped testing center, the production base has a daily output of over 100,000 units.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 17.0/100
- Industry
- Health
- Sector
- Ophthalmology, Orthopedic, Biotech and Pharma
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Apr 2026 | $14M | $55M | Real Power Capital · Nuoyu Capital | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ruanxin Biotechnology in its local ecosystem
The Ruanxin Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Real Power Capital- NCNuoyu Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ruanxin Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ruanxin Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









